Pituitary metastases: presentation and outcomes from a pituitary center over the last decade by Lithgow, Kirstie et al.
 
 
University of Birmingham
Pituitary metastases: presentation and outcomes
from a pituitary center over the last decade
Lithgow, Kirstie ; Siqueira, I ; Senthil, Latha; Chew, Han; Chavda, Swarupsinh; Ayuk, John;
Toogood, Andrew; Gittoes, Neil; Matthews, T; Batra, R; Meade, S; Sanghera, Paul; Khan, N;
Ahmed, S; Paluzzi, A; Tsermoulas, Georgios; Karavitaki, Niki
DOI:
10.1007/s11102-020-01034-2
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Lithgow, K, Siqueira, I, Senthil, L, Chew, H, Chavda, S, Ayuk, J, Toogood, A, Gittoes, N, Matthews, T, Batra, R,
Meade, S, Sanghera, P, Khan, N, Ahmed, S, Paluzzi, A, Tsermoulas, G & Karavitaki, N 2020, 'Pituitary
metastases: presentation and outcomes from a pituitary center over the last decade', Pituitary, vol. 23, no. 3, pp.
258–265. https://doi.org/10.1007/s11102-020-01034-2
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 14. Jun. 2020
Vol:.(1234567890)
Pituitary (2020) 23:258–265
https://doi.org/10.1007/s11102-020-01034-2
1 3
Pituitary metastases: presentation and outcomes from a pituitary 
center over the last decade
K. Lithgow1,2,3  · I. Siqueira1,2,3 · L. Senthil4 · H. S. Chew4 · S. V. Chavda4 · J. Ayuk2,3 · A. Toogood2,3 · N. Gittoes1,2,3 · 
T. Matthews5 · R. Batra5 · S. Meade6 · P. Sanghera6 · N. Khan7 · S. Ahmed7 · A. Paluzzi8 · G. Tsermoulas8 · 
N. Karavitaki1,2,3 
Published online: 18 March 2020 
© The Author(s) 2020
Abstract
Purpose Highlight and characterize manifestations, diagnostic/management approaches and outcomes in a contemporary 
cohort of patients with pituitary metastases (PM) from a large European pituitary center—over 10 years.
Methods Retrospective review of PM cases between 1/2009 and 12/2018. Clinical, laboratory, imaging data at PM detection 
and during follow-up were analysed.
Results 18 cases were identified (14 females; median age at diagnosis 61.5 years). Most common primary malignancies were 
lung (39%) and breast (32%). Most frequent presenting manifestation was visual dysfunction (50%). Gonadotrophin, ACTH, 
TSH deficiency were diagnosed in 85%, 67%, 46% of cases, respectively; diabetes insipidus (DI) was present in 17%. 33% 
of cases were detected during investigation for symptoms unrelated to PM. PM management included radiotherapy (44%), 
transsphenoidal surgery (17%), transsphenoidal surgery and radiotherapy (6%) or monitoring only (33%). One-year survival 
was 49% with median survival from PM detection 11 months (range 2–47).
Conclusions In our contemporary series, clinical presentation of PM has evolved; we found increased prevalence of anterior 
hypopituitarism, decreased rates of DI and longer survival compared with older literature. Increased availability of diagnos-
tic imaging, improvements in screening and recognition of pituitary disease and longer survival of patients with metastatic 
cancer may be contributing factors.
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Introduction
Pituitary metastasis (PM) is a rare manifestation of malig-
nancy [1–5]. The reported prevalence varies depending on 
the method of assessment; 0.4% in radiological [6], 1% in 
surgical [1, 7], and between 0.14 and 28.1% in autopsy series 
[1]. Proposed mechanisms of PM include direct hematog-
enous spread, spread via the hypothalamic-portal vessels, 
meningeal spread via the suprasellar cistern, or extension 
from juxtasellar or skull base metastases [1]. The posterior 
pituitary has been considered to be particularly susceptible 
to metastatic spread, mainly due to receiving blood supply 
from the systemic circulation, in contrast to the anterior 
gland which is supplied through the hypophyseal portal 
system [8].
Clinical presentation is variable and includes visual field 
impairment or optic neuropathy, cranial nerve palsies, ante-
rior pituitary dysfunction or diabetes insipidus (DI) [1–5, 9]. 
In earlier series, DI was a prominent presenting manifesta-
tion pointing towards the diagnosis of PM in a patient with 
known malignancy [1]. PM is most frequently detected in 
patients with a history of cancer, with breast and lung being 
the most common primary sites [1–5, 9]; it may also be the 
first manifestation of malignancy or detected incidentally 
[1, 3, 4, 6]. Imaging findings can be non-specific and are 
often not helpful in discriminating between PM and pituitary 
adenoma or other sellar lesion; however, rapid growth and 
invasion of parasellar structures should raise suspicion of 
pituitary metastatic infiltration [1, 3]. Management options 
include surgery and radiotherapy (alone or in combina-
tion), as well as, depending on the primary malignancy, 
chemotherapy, immunotherapy or hormonal therapy (such 
as tamoxifen for breast cancer). Evidence on the outcomes 
of these approaches is limited [7, 9–13], likely owing to the 
short survival of patients with PM.
Earlier diagnosis and appropriate management can poten-
tially impact the outcome and quality of life of patients with 
PM. A significant proportion of the literature in this field 
(case reports and small case series) was published over a 
decade ago [1, 2]. Given advances in the sensitivity and 
availability of diagnostic imaging, as well as in the treat-
ments and survival of cancer patients, it is anticipated that 
the presentation, natural history and prognosis of PM will 
have evolved, necessitating up to date information on con-
temporary clinical practice. Therefore, with this study, we 
aimed to elucidate the presenting manifestations, diagnostic 
and management approaches, as well as the outcomes of 
patients with PM from a large Pituitary center in Europe 
over the last 10 years.
Patients and methods
Records of all cases with the diagnosis of PM included in 
the Pituitary Registry of the Department of Endocrinol-
ogy, Queen Elizabeth Hospital Birmingham, UK between 
1/2009 and 12/2018 were reviewed. Eligible cases had either 
histopathological confirmation of PM, or were diagnosed 
based on clinical and radiological features (history of under-
lying malignancy and imaging confirming the presence of 
a sellar mass with features, according to expert neuroradi-
ology review, suggestive of metastatic infiltration or with 
rapid increase in its size). Clinical, laboratory and imag-
ing data, as well as management approaches and outcomes 
were collected. Imaging characterization of the PM relied 
on brain and pituitary MRIs (pre- and post-contrast, T1- and 
T2-weighted images). Management approach for each PM 
case was individualized based on the decisions of the mul-
tidisciplinary oncology, neurosurgical and endocrine team.
Gonadotrophin deficiency was diagnosed based on low 
or inappropriately normal gonadotrophins with serum tes-
tosterone below the reference range in men, low or inappro-
priately normal gonadotrophins with low serum estradiol 
in premenopausal women, and gonadotrophins below the 
reference range for age in post-menopausal women. TSH 
deficiency was defined based on free T4 below the reference 
range in the presence of a low or inappropriately normal 
TSH value. ACTH deficiency was defined based on a 0900 h 
serum cortisol < 100 nmol/L in the absence of exogenous 
corticosteroid therapy, or an inadequate response to the 250 
mcg short Synacthen test. DI was defined based on the pres-
ence of hypotonic polyuria with increased serum osmolality 
or serum sodium above the reference range and subsequent 
therapeutic response to desmopressin. Patients on medica-
tions potentially affecting pituitary hormone axes (e.g. opi-
oids, glucocorticoids) were not included in the evaluation 
of the rates of pituitary hormone deficits attributed to PM.
The study was retrospective and involved no interven-
tion beyond routine patient care. It was registered with and 
approved as an audit by the University Hospitals Birming-
ham NHS Foundation Trust.
Statistical analysis
Percentages were calculated for categorical data and medi-
ans with ranges for continuous variables. Tumor progres-
sion-free curves and overall survival curves were generated 
by the Kaplan–Meier method. Statistical analyses were per-
formed by IBM SPSS Statistics for Windows, Version 22.0. 
Armonk, NY: IBM Corp.
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Results
Eighteen cases were identified [14 females and 4 males 
with median age at PM detection 61.5  years (range 
44–75)]. Their clinical characteristics are shown in 
Table 1. In all patients who underwent biopsy or surgical 
resection, the diagnosis of PM was confirmed by positive 
pathology (n = 8); in the remaining ones, diagnosis was 
based on clinical/radiological features.
Primary malignancy was lung cancer (39%, n = 7), 
breast cancer (33%, n = 6), prostate cancer (11%, n = 2), 
melanoma (11%, n = 2) and renal cell carcinoma (6%, 
n = 1). In 72% (n = 13) of the cases, there was a known 
history of malignancy [median time from diagnosis of pri-
mary tumor to PM detection 29 months (range 10–244)]. 
In the remaining 28% (n = 5), PM was the first manifesta-
tion leading to diagnosis of the primary cancer; this group 
had presented with cranial nerve palsy (n = 1), visual fields 
deficit (n = 1), neurological symptoms related to synchro-
nous metastatic deposit elsewhere in the brain (n = 2) and 
rapid growth of a pituitary mass during follow-up of a pre-
sumed macroadenoma (n = 1). Other metastases at the time 
of PM detection were known in 72% (n = 13) of patients. 
Amongst the breast cancers, human epidermal growth fac-
tor receptor 2 (HER2) was overexpressed in 60% (n = 3/5) 
and 100% (n = 5/5) were estrogen receptor positive.
Visual dysfunction was the most common presenta-
tion of PM [50%, n = 9; disturbances of visual fields and/
or visual acuity (n = 5) or cranial nerve palsies (n = 4)]. 
Clinical features of hypopituitarism were described in 17% 
(n = 3); two patients had symptoms of cortisol deficiency 
and one had manifestations of DI. In 33% (n = 6), PM 
was detected during investigations for reasons unrelated 
to pituitary disease [neurological symptoms secondary to 
other brain metastases (n = 4), staging of the primary can-
cer (n = 1) and to re-evaluate a previously known menin-
gioma (n = 1)]. Gonadotrophin deficiency was diagnosed 
in 85% (11/13), ACTH deficiency in 67% (8/12), TSH 
deficiency in 46% (6/13) and DI was found in 17% (3/18) 
of the patients. Formal visual review revealed optic nerve 
dysfunction (visual field and/or visual acuity compromise) 
in 57% (8/14) and cranial nerve palsies in 22% (4/18) of 
the cases. On pituitary MRI, suprasellar extension was 
seen in 94% (17/18), cavernous sinus extension in 39% 
(7/18), sphenoid sinus invasion in 11% (2/18) and exten-
sion through the sellar floor to the clivus in 22% (4/18) of 
the patients.
Management decisions were individualised and were 
based on the outcome of multidisciplinary team meetings; 
the main indication for surgery was visual deterioration 
and this option was adopted whenever possible. Primary 
management for PM was fractionated radiotherapy in 44% 
(n = 8), transsphenoidal surgery in 17% (n = 3), transsphe-
noidal surgery with adjuvant fractionated radiotherapy in 
6% (n = 1) and monitoring only in 33% (n = 6). Follow-
up imaging was available for ten cases [median monitor-
ing 9 months (range 2–45)]. In the remaining eight, this 
was not arranged due to limited life expectancy (n = 6, all 
died within 12 months of diagnosis) or because follow-up 
of PM was done with neuro-ophthalmology assessment 
(n = 2, one case died 37 months after diagnosis and the 
second remained alive at time of last review 3 months after 
PM diagnosis). Of the ten cases with follow-up imaging 
(managed by radiotherapy n = 3, surgery n = 2, surgery and 
radiotherapy n = 1, monitoring n = 4), radiological pro-
gression was seen in seven at a median time of 9 months 
(range 3–45) since primary PM management. Four of these 
patients [previously managed by transsphenoidal surgery 
(n = 1) or monitoring (n = 3)] required intervention due 
to threat to vision [transsphenoidal surgery with adjuvant 
fractionated radiotherapy (n = 2), fractionated radiotherapy 
(n = 1), or transsphenoidal surgery (n = 1)]. A second epi-
sode of PM radiological progression was detected in one 
patient 10 months after pituitary surgery and radiotherapy 
and was managed by another course of external irradiation.
At last follow-up, gonadotrophin deficiency was pre-
sent in 92% (12/13), ACTH deficiency in 82% (9/11), TSH 
deficiency in 64% (9/14) and DI in 22% (4/18). Patients 
were on glucocorticoid, levothyroxine, and desmopressin 
replacement as appropriate. Gonadal hormone replacement 
was not offered in any of the cases. Eight of the 11 cases 
with baseline optic nerve dysfunction had follow-up visual 
assessment; vision was improved in four, stable in two and 
deteriorated in two cases.
Median clinical follow-up (from imaging detecting PM 
until last assessment or death) was 11 months (range 2–47). 
During this period, 13 patients died as a result of their malig-
nancy at a median time from PM detection 11 months (range 
1–37) [median age at death 63 years (range 52–74)]. The 
probability of survival was 49% and 37% at 1 and 2 years, 
respectively (Fig. 1).
Discussion
In this series of patients presenting with PM over the last 
decade in our pituitary centre, we reviewed their clinical 
characteristics and outcomes. Compromised vision was the 
most common presenting manifestation, whereas DI was 
less frequent than described in earlier studies. In around one 
third of the cases, PM was detected during investigations for 
symptoms not related to pituitary disease. Importantly, sur-
vival was 49% at 1 year, reflecting advances in the diagnosis 
and management of malignant disease.
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In agreement with previous literature [1, 4, 5, 9], we 
found that lung and breast were the predominant primary 
sites of malignant disease; nonetheless, pituitary metastatic 
infiltration can be seen in almost any type of malignancy [1, 
4, 5, 9]. In a recently published study, breast cancers over-
expressing HER2 seemed to be more prone to metastasise 
to the pituitary gland [9]. In our breast cancer cases, HER2 
was overexpressed in 60%.
Compromised vision was the most common presenting 
manifestation of PM found in 50% of our cases and further 
formal visual review revealed optic nerve dysfunction in 
57%. He et al. [2] and Schill et al. [9] reported rates visual 
loss of 41% and 42%, respectively, as opposed to 27% from a 
review of cases published in 2004. Increased availability and 
improvements in neuro-ophthalmological assessment allow-
ing detection of more subtle visual disturbances could be a 
potential explanation for this rise. Anterior hypopituitarism 
was diagnosed in a significant number of our cases. Despite 
this, symptomatology of hypopituitarism was the presenting 
manifestation in a much lower rate of patients. The possi-
bility that the symptoms and signs of hypopituitarism were 
attributed to the underlying malignancy and, at least initially, 
were not associated with PM cannot be excluded. Further-
more, DI was present in only 17% of the cases suggesting 
that the clinical presentation of PM has evolved. In earlier 
literature, posterior lobe dysfunction was more common than 
anterior hypopituitarism [8], and DI was the most frequent 
presenting manifestation of PM, even reported at 100% 
in some series [1]. Our findings and other recent publica-
tions contradict this. He et al. [2] in a systematic review and 
pooled analysis of 248 PM cases, compared clinical features 
of 190 patients previously reviewed by Komninos et al. [1] 
(published 1970–2002) with 58 cases reported from 2004 
to 2011. Their analysis demonstrated that the later 58 cases 
had significantly lower rates of DI and higher rates of visual 
dysfunction, cranial nerve palsies and anterior pituitary dys-
function [2]. Furthermore, in a recently published nation-
wide series of 38 cases of PM, majority of which presented 
between 2011 and 2013, rates of DI were 26%, of gonadotro-
phin deficiency 88%, of TSH deficiency 65%, and for ACTH 
deficiency 71% [9]. Factors explaining this change may be 
the earlier detection of PMs, increased awareness of mani-
festations of hypopituitarism, as well as better availability 
and wider use of relevant biochemical testing. Furthermore, 
improvements in cancer screening and diagnosis in general 
may also contribute to early detection of PM.
PM was the first manifestation of malignancy in 28% of 
our patients. This rate varies in the literature between 25 
and 64% [1, 3, 4, 14] and may be influenced by the differ-
ences in the primary malignancies included in various series. 
Schill et al. reported that 63% of PM from lung cancers were 
detected before or within the first year after diagnosis of the 
primary tumour, whereas 53% of PM from breast cancers Ta
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were detected 10 years or more after diagnosis of the pri-
mary tumour [9]. Notably, in our series, all cases where PM 
was the first manifestation of malignancy had a lung pri-
mary. Time of publication may also be a contributing factor; 
the highest proportions of PM as the first manifestation of 
malignancy were seen in older series [1, 14], potentially 
reflecting improved screening and earlier diagnosis of com-
mon primary malignancies in recent decades. In 33% of our 
cases, PM was detected during investigations for symptoms 
not related to pituitary disease. The prevalence of PM which 
are latent at detection has not been previously well-charac-
terised. However, the pooled prevalence of PM is higher 
in autopsy series compared with that of clinical or surgical 
ones [1, 2], suggesting that many cancer patients have latent 
PM which may be detected incidentally.
Differential diagnosis of PM from other sellar lesions is 
often difficult and poses challenges, especially when there 
is no history of primary malignancy. Signal characteris-
tics on MRI are variable and include hypointensity on T1 
weighted imaging, hypo- or hyperintensity on T2 weighted 
imaging, and post-contrast enhancement [1, 4, 9]. Extension, 
particularly suprasellar, is common [9], and a “dumbbell” 
shape on sagittal view is frequently seen [1, 4, 9]. How-
ever, extension is not always present; some PMs present as 
a sellar mass or with thickening of the pituitary stalk [3]. 
Other imaging features include infiltration into adjacent tis-
sues and rapid increase in size [1, 4]. Increased uptake on 
18F-fluorodeoxyglucose (FDG) positron emission tomogra-
phy-computed tomography (PET/CT) has been observed in 
PM, however this is a non-specific finding as it can also be 
observed in pituitary adenomas, hypophysitis, Langerhans 
cell histiocytosis or indeed normal pituitary tissue [15].
The management of PM which also depends on the 
extent of systemic disease, aims to provide symptomatic 
relief (mainly of visual disturbances) with a favourable 
impact on quality of life and to prevent further enlargement 
of the lesion. In our series, visual disturbances improved 
or remained stable in 75% of the patients with available 
follow-up data. Visual outcomes following treatment have 
been reported in a limited number of studies; improvements 
in vision and cranial nerve dysfunction have been described 
in 30–100% and 50–100%, respectively after surgery [7, 
Fig. 1  Survival of the patients since the diagnosis of pituitary metastasis
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12, 13]. Stereotactic radiosurgery (SRS) has been shown to 
be effective for controlling growth of PM [10, 11, 16] and 
improvement in cavernous sinus cranial nerve palsies has 
been observed following SRS [10, 11, 16]. Hypofractionated 
SRS has shown promise for pituitary adenomas in achieving 
tumour control with low toxicity to the optic pathway [17], 
though experience with this strategy for PM is thus far lim-
ited to a small case series [18]. Progression of PM depends 
on the type and stage of primary malignancy, management 
strategies and duration of follow-up and relevant data are 
scarce [7, 9–13]. In our series, 7 out of 10 patients with 
available imaging showed PM progression at a median time 
of 9 months since primary PM management, which in 57% 
of cases included monitoring.
Survival after the diagnosis of PM depends on the type 
and stage of primary cancer. Historically, PM had been 
associated with aggressive disease, end stage malignancy, 
and reduced life expectancy [1] with earlier series reporting 
mean survival of 6–7 months [1]. Ntyonga-Pono et al. [19] 
in a group of patients presenting prior to 1999 reported that 
only 10% lived beyond 1 year. However, survival after PM 
detection appears to be improving over time, possibly due 
to earlier diagnosis of pituitary metastatic infiltration and to 
improved life expectancy of cancer patients. In our series, 
survival was 49% and 37% at 1 and 2 years, respectively. 
This rate may be also be influenced by referral bias as in 
our tertiary center more advanced cancer cases are likely 
to be referred. In agreement with our data, Schill et al. [9] 
demonstrated 1 year survival of 50% in a series of patients 
diagnosed with PM between 1996 and 2018. Recognition 
that a large proportion of patients with PM may survive 
beyond 1 year is clinically significant, as it will facilitate 
decisions on interventions aimed at restoring vision or pre-
venting visual loss, and improving quality of life.
Limitations of our study include its small size and retro-
spective design (although prospective studies for this rare 
condition may not be a realistic goal) and the lack of patho-
logical confirmation of PM in a number of cases. Nonethe-
less, the rapid mass enlargement and the imaging appear-
ances not consistent with a benign mass were in favour of 
metastatic disease. Advantages include its focus on contem-
porary practice of the last 10 years from a large pituitary 
centre in Europe and the reasonable follow-up duration after 
PM detection allowing survival analysis.
In our single centre cohort of PMs, we illustrate the pres-
entation and outcomes of PM in the era of increasing sur-
vival of cancer patients and wide availability of diagnostic 
imaging. We found increased prevalence of anterior hypo-
pituitarism and decreased rates of DI possibly also related 
with improvements in screening for pituitary dysfunction. 
However, 33% of our cases were detected during investi-
gations for symptoms not related with pituitary disease 
suggesting that clinicians should be alert for screening for 
hypopituitarism in patients with known malignancy, par-
ticularly in breast or lung. The improvement in survival is 
encouraging and can guide decisions on decisions for active 
therapeutic interventions for the PM that will provide benefit 
to the patients (e.g. resolution of visual disturbances with 
favourable impact on quality of life). Further outcome-ori-
ented studies are needed to determine the safety and efficacy 
of different management strategies for PM.
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